

### PRELIMINARY LIST OF SCIENTIFIC PRESENTATIONS

#### MOLECULAR SURVIVAL AND REGENERATION IN CARDIAC DISEASE

**Cell Longevity Pathways Govern Vascular and Inflammatory Responses to Oxidant Stress** 

Kenneth Maiese, New Jersey Medical School, Newark, NJ, USA

Calpain-Mediated Dystrophin Disruption may be a Potential Structural Culprit Behind Chronic Doxorubicin-Induced Cardiomyopathy

Marcos A Rossi, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil

Stem Cells and Vascular Disease

Qingbo Xu, Kings College London, UK

The Effects of Risk Factors on Endothelial Progenitor Cells in Cardiovascular Diseases

**Shing-Jong Lin,** National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan

The Conundrum of Myocardial Regeneration *Werner Mohl*, Medizinische Universität Wien, Vienna, Austria

MicroRNAs in Relation to Metabolic Syndrome and Cardiovascular Diseases *Paul Holvoet*, Katholieke Universiteit Leuven, Belgium

Mitochondrial Fission and Fusion in Heart Disease Anne A. Knowlton, University of California, Davis, USA

Regulation of Cell Death Pathways in the Heart Lorrie A. Kirshenbaum, St. Boniface Research Centre, Winnipeg, Manitoba Canada

Redox Regulation of Autophagy in Heart

Dipak K. Das, University of Connecticut School of Medicine Farmington, CT, USA

Heart Regeneration Using iPS Cells Keiichi Fukuda, Tokyo, Japan

Nanomedicine - The Clinician's Perspective Israel Rubinstein, University of Illinois College of Medicine, Chicago, IL, USA

#### **VASCULAR BIOLOGY**

Gene Delivery to Regulate Vascular Smooth Muscle Function

James D. Marsh, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Novel Ligands and Reactions Mediated by Oxidized LDL Receptor LOX-1 *Tatsuya Sawamura*, National Cerebral and Cardiovascular Center Fujishirodai, Suita, Osaka, Japan

### Regulation of Myocardin Activity in Vascular Smooth Muscle

Xi-Long Zheng, The University of Calgary, AL, Canada

### Carbamylation Versus Oxidation of LDL: Competition, Mechanisms and Role in Cardiovascular Disease

*Alexei G. Basnakian*, University of Arkansas for Medical Sciences, Little Rock, AR, USA

### ACE2 as a Novel Target for CVD

Mohan K. Raizada, University of Florida, Gainesville, FL, USA

#### A GLIMPSE TO THE FUTURE - GENETICS OF HEART DISEASE

### **Genetics of Coronary Artery Disease**

Robert Roberts, University of Ottawa Heart Institute, ON, Canada

### Family Based Studies of the Genetics of Congenital Heart Defects

**Neil E. Bowles**, University of Utah School of Medicine, Eccles Institute of Human Genetics, Salt Lake City, UT, USA

#### miRNAs, DNA Variants and Heart Failure

**Jennifer L. Hall**, Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, USA

### Multidisciplinary Approach to Genome-Wide Association Study (GWAS) for Heart Failure Based on the Different Ethnicity

Teruhiko Toyo-Oka, University of Tokyo, Japan

### Cardiac Hypertrophy and Remodeling in NPR1-Gene-Disrupted Mice: Role of Pro-Inflammatory Cytokines

*Kailash N. Pandey*, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA, USA

#### Cardiovascular Contributions to Neurological Disease

Yuqing Li, College of Medicine University of Florida, Gainesville, FL, USA

#### **Genetic Factors Influencing Left Ventricular Hypertrophy**

Jonathan N. Bella, Bronx-Lebanon Hospital Center, Bronx, NY, USA

### Impact of Beta-Adrenergic Receptor Polymorphism on Non-Invasive CAD Testing

Jamshid Shirani, St. Luke's Hospital and Health Network, Philadelphia, PA, USA

### Critical Regulatory Roles of TGFbeta/BMP Signaling Pathways during Myocaridal Wall Development

Kai Jiao, The University of Alabama at Birmingham, AL, USA

#### PLATELETS AND INFLAMMATION IN ISCHEMIC HEART DISEASE

#### **Platelet Function and Clinical Ischemic Outcomes**

Lewis C. Becker, Johns Hopkins University School of Medicine, Baltimore, MD, USA

## **C-reactive Protein-Mediated Endothelial Dysfunction and Acute Coronary Artery Disease**

Janos G. Filep, University of Montreal, QC, Canada

## Inflammation and Acute Coronary Syndrome: Mechanistsic Role and Clinical Implications

Thomas F. Luscher, University Hospital Zurich, Switzerland

### **C-Reactive Protein and Coronary Vasomotor Regulation**

Lih Kuo, Texas A&M Health Science Center, Temple, TX, USA

Cigarette Smoke Induces Fractalkine-Dependent Mononuclear Cell Arrest to the Arterial Endothelium. Potential consequences in COPD

Maria J. Sanz, Universidad de Valencia, Spain

Immunizations and Acute Coronary Syndromes: Is there a Role?

Maliha Zahid, University of Pittsburgh, Pittsburgh, PA, USA

Coronary Plaque Erosion and Myeloperoxidase: Insight from a

**Clinicopathological Study** 

Giampaolo Niccoli, Catholic University of the Sacred Heart, Rome, Italy

#### **NOVEL CARDIOPROTECTIVE THERAPIES**

Early Insulin Treatment Ameliorates Post-Ischemic Heart Failure by Iinhibition of Myocardial CaMKII via PI3K-Akt Activation

Feng Gao, The Fourth Military Medical University, Xi'an, China

The role of MyD88 in the anti-apoptotic effects of Interleukin-10

Pawan K. Singal, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada

Augmentation of the Cardiac Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors with Cilostazol

Yochai Birnbaum, Baylor College of Medicine, Houston, TX, USA

### **CETP Modulation as a Therapeutic Approach**

**Wolfgang Koenig**, Internal Medicine II-Cardiology University of Ulm Medical Center, Germany

Molecular Mechanism of AMP Activated Protein Kinase and Metformin in Protecting Ventricular Function

Yingjie Chen, University of Minnesota, Minneapolis, MN, USA

Therapeutic Potential of Tissue Inhibitor of Metalloproteinases >(TIMPs) in Heart Disease

Zamaneh Kassiri, University of Alberta, Edmonton, AB, Canada

Tricyclic Psychiatric Antidepressants as Alpha2a Adrenergic Receptor Ligands Modulating Receptor Function

Qin Wang, University of Alabama at Birmingham, AL, USA

### EMERGING MOLECULAR PARADIGMS IN MYOCARDIAL ISCHEMIA, INFARCTION AND REMODELING

Lineage Markers in Tracking Cardiac Fibroblast Fate in Vivo and In Vitro Carlin S. Long, University of Colorado Health Sciences Center, Denver, CO, USA

p90RSK Inhibits CHIP Ubiquitin E3 Lligase Activity via ERK5, and Promotes Cardiac Apoptosis and Dysfunction after Myocardial Infarction in Diabetes. *Jun-ichi Abe*, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

Negative Regulation of Toll Like Receptor (TLR)/Interleukin-1 (IL-1) Signaling in Cardiac Repair

Nikolaos Frangogiannis, Albert Einstein College of Medicine, Bronx, NY, USA

### microRNA Inhibits Cardiac Remodeling in the Infarcted Myocardium

Dinender K. Singla, University of Central Florida, Orlando, FL, USA

## Role of Autophagy in the Human Heart Exposed to latrogenic Ischemia/Reperfusion Injury

Tiziano M. Scarabelli, Wayne State University School of Medicine, Detroit, MI, USA

### CARDIOVASCULAR IMAGING FOR EVALUATION OF CARDIAC STRUCTURE AND FUNCTION

#### **Progress in Echocardiography**

Navin C. Nanda, University of Alabama at Birmingham, Birmingham, AL, USA

#### 3D Echo in Clinical Practice

**Smadar Kort**, Stony Brook University Medical Center Health Sciences, Stony Brook, NY, USA

### 3-D TEE for the Mitral Valve

Stamatios Lerakis, Emory University Hospital, Atlanta, GA, USA

# Valvular Heart Disease: Can MRI Trump the Echocardiogram? Robert W.W. Biederman, University Allegheny General Hospital, Pittsburgh, PA, USA

Novel Echocardiographic Indices of Left Ventricular Diastolic Function Sherif F. Nagueh, Methodist DeBakey Heart and Vascular Center, Houson, TX, USA

Stress Echocardiography. Diagnosis, Prognosis and Recent Advances *Abdou Elhendy*, Marshfield, WI, USA

Review of Movahed's Sign (D shaped left ventricle seen on gated SPECT)
Suggestive of Right Ventricular Overload

Mohammad-Reza Movahed, University of Arizona Sarver Heart Center, Tucson,

AZ, USA

### **Usefulness of OCT in Clinical Practice**

Takashi Akasaka, Wakayama Medical University, Japan

Cardiac CT: Beyond coronary imaging *Milind Y. Desai*, Cleveland Clinic, OH, USA

#### **IMAGING ATHEROSCLEROSIS AND DIAGNOSIS OF CAD**

Vulnerable Plaque and Vulnerable Patient: Insights from IVUS and OCT *Hiroyuki Okura*, Kawasaki Medical School, Kurashiki, Japan

Non-Invasive Ultrasound Evaluation of Subclinical Atherosclerosis: Progress and Pitfalls

Julius M. Gardin, Hackensack University Medical Center, Hackensack, NJ, USA

Early Identification of Subclinical Atherosclerosis: The Most Effective Way to Reduce Significantly the Incidence of Coronary Artery Disease Shorena Chumburidze, Scientific Research Clinic of Therapy, Tibilsi, Georgia

#### **Blood Flow Dynamics and the Atherosclerotic Plaque**

**Stephanie Lehoux**, Lady Davis Institute for Medical Research McGill University, Montreal, Canada

## **Evaluation of Chest Pain in the Emergency Department: A Patient-Centered Imaging Approach**

**John J. Mahmarian**, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA

### **Cardiac CT - Diagnosis and Prognosis**

Benjamin J.W. Chow, University of Ottawa Heart Institute, Ottawa, ON, Canada

A Novel Application of Exercise Treadmill Testing in a Cardiology Practice *Yzhar Charuzi*, UCLA School of Medicine, Los Angeles, CA, USA

### **Diagnostic Accuracy of Exercise Echocardiography**

*Maria Prokudina*, Federal Center of Heart, Blood and Endocrinology, St. Petersburg, Russia

### HEART FAILURE: NOVEL RISK FACTORS, BIOMARKERS, PREVENTION AND NEW TREATMENT OPTIONS

International Clinical Trials: Good for the New World Bad for the Third World Sidney Goldstein, Henry Ford Hospital, Detroit, MI, USA

#### **Aging and Heart Failure**

Bodh I. Jugdutt, University of Alberta and Hospitals, Edmonton, Alberta, Canada

#### **Steps to Prevent Heart Failure**

*Hanumanth K. Reddy*, University of Arkansas for Medical Sciences, Little Rock, AR, USA

### Baroreflex Stimulation for the Treatment of Heart Failure

Hani N. Sabbah, Henry Ford Hospital, Detroit, MI USA

### Novel Hemodynamic Risk Factors for New - Onset Heart Failure in the General Population

*Julio A. Chirinos*, University of Pennsylvania School of Medicine Philadelphia, PA, USA

#### Management of Patient with Advanced Heart Failure

*Maria Vittoria H. Pitzalis*, East Carolina University, The Brody School of Medicine, Greenville, NC, USA

## Blood Urea Nitrogen: An Emerging Biomarker for Neurohormonal Activation in Heart Failure

Amir Kazory, University of Florida, Gainesville, FL, USA

### Cardiorenal Syndromes: New Diagnostic and Therapeutic Targets

**Peter A. McCullough**, St. John Providence Health System, Providence Park Heart Institute, Novi, MI, USA

Aldosterone Antagonists in Heart Failure: Clinical Settings and Timing"or Alternatively "Acute Heart Failure Syndromes: Currents Trends in Classification and Management Chris Adamopoulos, Greece

#### Diet for the Prevention and Management of Heart Failure

*Christina Chrysohoou*, First Cardiology Clinic, Hippokration Hospital, School of Medicine, University of Athens, Greece

### Increased Renal ENaC Subunits and Sodium Retention in Rats with Chronic Heart Failure

Hong Zheng, University of Nebraska Medical Center, Omaha, NE, USA

### NEW INSIGHTS INTO THE PATHOGENESIS, PREVENTION AND TREATMENT OF CARDIOMYOPATHIES

## Mechanisms of Cardiac Dysfunction in Diabetic Cardiomyopathy *Naranjan S. Dhalla*, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada

Peripartum Cardiomyopathy: Etiology, Diagnosis, Prognosis and Management *Uri Elkayam*, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

Aptamers for Binding and Neutralization of Pathogenic Autoantibodies Directed to the Beta1-Receptor and Found in Patients with Cardiomyopathy. Is there a New Treatment Option?

*Ingolf Schimke*, Charité - Universitätsmedizin Berlin, Medizinische Klinik (Kardiologie), Berlin, Germany

#### **Cardiotoxicity of Cancer Therapy**

Jennifer Liu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Mechanisms of LVOT Obstruction in Hypertrophic Cardiomyopathy: New Mechanistic Insights from 3-Dimensional Echocardiography *Jae-Kwan Song*, Asan Medical Center, Seoul, South Korea

Alcohol Septal Ablation vs. Septal Myectomy for HOCM: When to do Which *Michael A. Fifer*, Massachusetts General Hospital, Boston, MA, USA

Iron-overload Cardiomyopathy: Pathophysiology, Diagnosis, and Treatment *Gavin Y. Oudit*, Mackenzie Health Sciences Centre Edmonton, Alberta, Canada

Prevention of Heart Failure 2012: Epidemiologic Perspectives

Andreas P. Kalogeropoulos, Emory Clinical Cardiovascular Research Institute

Emory University, Atlanta, GA, USA

The Degradation System in Cardiomyocytes

Osamu Yamaguchi, Osaka University Graduate School of Medicine, Japan

#### **CARDIAC ELECTROPHYSIOLOGY AND DEVICES - 2012 UPDATES**

Cardiac Arrhythmias in the Elderly-Management Issues

Adarsh Kumar, Govt. Medical College/G.N.D. Hospital, Amritsar, Punjab, India

New Insights into Identification of Patients at Risk for Sudden Cardiac Death *Michael E. Cain*, University at Buffalo, Buffalo, NY, USA

Is Cardiac Resynchronization Therapy Proarrhythmic? *Anne Curtis*, University of Buffalo, Buffalo, NY, USA

#### Do RV Apical Pacing Should be Avoided?

I. Eli Ovsyshcher, Ben-Gurion University, Soroka University Medical Center, Beer Sheva. Israel

Novel Technologies for Atrial Fibrillation Diagnosis and Interventional Treatment *Andreas Bollmann*, University Leipzig, Germany

#### **ARRYTHMOGENIC CARDIOMYOPATHIES**

The Prevalence and Prognostic Significance of Early Repolarization (J wave) in Brugada syndrome

*Masahiko Takagi*, Osaka City University Graduate School of Medicine, Osaka, Japan

Arrhythmogenic Right Ventricular Cardiomyopathy: Disease of the Desmosome with Multiple Clinical Presentations

Firat Duru, University Hospital of Zurich, Switzerland

Heart Failure and AICD'S: Time to go beyond the Initial Shock

Juan M. Aranda, University of Florida College of Medicine, Gainesville, FL, USA

Diagnostic Significance of Tc-99m-Pyp Radionuclide Myocardial Scintigraphy, Evaluating Possible Presence, Severity of Sarcoid Cardiomyopathy and Sudden Cardiac Death Risk Prevention in 178 Systemic Sarcoidosis Patients Studied

**Nestor I. Angomachalelis**, Aristotle University School of Medicine, Thessaloniki, Greece

#### ATRIAL FIBRILLATION - NEW RISK FACTORS AND THERAPIES

Metabolic Syndrome and Dyslipidemia as Risk Factors for Atrial Fibrillation *Hiroshi Watanabe*, Niigata University Graduate School of Medical & Dental, Japan

Genotype-Based Atrial Fibrillation Therapies

Daniela Husser, University Leipzig Heart Center, Germany

Cryoablation of Atrial Fibrillation: Is it ready for Primetime? *Komandoor Srivathsan*, Mayo Clinic Arizona, Phoenix, AZ, USA

Atrial Fibrillation Ablation using Anatomically Designed Catheters and Under Direct Vision

Thomas Deneke, University of Bochum, Germany

New Anticoagulants in Atrial Fibrillation. Are all the Same? *Antoni Martinez-Rubio*, Hospital de Sabadell, Barcelona, Spain

Anticoagulation and Atrial Fibrillation. Antithrombotics State of the Art *Karlheinz Seidl*, Klinikum Ingolstadt, Ingolstadt, Germany

#### HYPERTENSION: FROM GENETICS TO RECENT ADVANCES IN THERAPY

Emerging Molecular Mechanisms of Pulmonary Arterial Hypertension: Are we Closer to a Cure?

**Duncan J. Stewart**, Ottawa Health Research Institute, The Ottawa Hospital, ON. Canada

Recent Advances in the Therapy of Pulmonary Arterial Hypertension *Robert C. Bourge*, University of Alabama at Birmingham, AL, USA

Role of Echocardiography in Pulmonary Arterial Hypertension. From Diagnosis to Prognosis

Eduardo Bossone, Cava de Tirreni & Amalfi Coast Hospital, Italy

### Hypertension in Elderly

Wilbert S. Aronow Cardiology Division, New York Medical College, Valhalla, NY. USA

### Blood Pressure Targets for Patients with Coronary Artery Disease: is Lower Better?

*Clive Rosendorff*, Mount Sinai School of Medicine, New York, NY and James J. Peters VA Medical Center, Bronx, NY, USA

How Important is the Recognition of White-Coat Hypertension and Masked Hypertension for the Appropriate Treatment of the Diabetic and other High-Risk Patients with Cardiovascular Disease?

Stanley S. Franklin, University of California, Irvine, CA, USA

### Sleep -Time Blood Pressure as a Therapeutic Target for Cardiovascular Risk Reduction

Ramon C. Hermida, Campus Universitario, Vigo, Spain

### Renal Denervation - State of the Art

*Horst Sievert*, Cardiovascular Center Frankfurt Sankt Katharinen, Frankfurt, Germany

Prehypertension: Not a Benign Vascular Condition

Christopher DeSouza, University of Colorado, Boulder, CO, USA

My Patient Cannot Stand Up: What to do about Orthostatic Hypotension Satish R. Raj, Vanderbilt University School of Medicine, Nashville TN USA

### **OBESITY, METABOLIC SYNDROME AND DIABETES**

#### The Obesity Paradox and Cardiovascular Disease

*Martin A. Alpert*, University of Missouri-Columbia School of Medicine, Columbia, MO, USA

#### The Burden of Diabetes

Elizabeth Barrett-Connor, University of California San Diego, La Jolla, CA, USA

### Endothelial Dysfunction in Hypertension, Diabetes and Obesity

Tadeusz Malinski, Chemisty and Biochemistry Ohio University, Athens, OH, USA

### Screening for Atherosclerosis in Metabolic Syndrome and Diabetes?

Nathan D. Wong, Division of Card University of California, Irvine, CA, USA

### Cardiovascular Disease Prevention in Patients with Diabetes Gordon L. Fung, UCSF Medical Center at Mt. Zion, San Francisco, CA, USA

Refining Risk Assessment in Diabetic Dyslipidemia after Achieving LDL-C Goal *Om P. Ganda*, Harvard Medical School, Boston, MA, USA

### Genetic Risk Factors for Cardiovascular Disease in Type 2 Diabetes

Lu Qi, Harvard School of Public Health, Boston, MA, USA

#### DIET, LIFESTYLE AND CARDIOVASCULAR DISEASE

#### Cardiovascular Prevention - A Global Problem

Ulrich Keil, University of Muenster, Germany

### Molecular Mechanisms of the Beneficial Cardiovascular Effects of Trans-Resveratrol

*Ulrich Forstermann*, Johannes Gutenberg University Medical Center Obere Zahlbacher Strasse, Mainz, Germany

#### Vitamin D and CVD

Vera Bittner, University of Alabama at Birmingham, AL, USA

#### Coffee Drinking and Risk of Stroke

Arthur L. Klatsky, Kaiser Permanente Medical Center, Oakland, CA, USA

## Multivitamins and other Supplements for the Prevention of Cardiovascular Disease: Hope or Hype?

Howard D. Sesso, Brigham and Women's Hospital, Boston, MA, USA

### Diet and Secondary Prevention of Cardiovascular Disease: The Current Level of Evidence

Demosthenes B. Panagiotakos, Dietetics Harokopio University of Athens, Greece

### Lifestyle Factors and the Risk of Cardiovascular Disease

Gang Hu, Pennington Biomedical Research Center, Baton Rouge, LA, USA

### Smoking Cessation...and What Role for the Cardiologist?

Sandeep Gupta, Whipps Cross and St. Bartholomew's Hospitals, Leytonstone, UK

### PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE – RISK FACTORS AND PREVENTION

### Diurnal Rhythms and the Pathogenesis of Cardiovascular Disease

Michael J. Sole, University of Toronto, Toronto, ON, USA

### Intestinal Lipid Mediators, Systemic Inflammation and Cardiovascular Disorders

*Mohamad Navab*, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

### Coronary and Aortic Calcium in Predicting Cardiovascular Events and Mortality

Michael H. Criqui, University of California San Diego, La Jolla, CA, USA

### Oxytocin - An Antiobesity and Cardioprotective Molecule

Daniela Jezova, Institute of Experimental Endocrinology, Bratislava, Slovakia

### Psychosocial Risks, Mental Stress Induced LV Dysfunction, and CHD (Coronary Heart Disease) Outcome?

Wei Jiang, Duke University Medical Center, Durham, NC, USA

### Statins for the Primary Prevention of CVD in Women

Samia Mora, Brigham and Women's Hospital, Boston, MA, USA

### Acute Respiratory Infections as Triggers for Cardiovascular Events

Mohammad Madjid, Texas Heart Institute, Houston, TX, USA

### From Surrogate Biomarkers to Detection of Atherosclerosis: Are We Ready for a Paradigm Shift in Primary CVD Prevention Strategies?

Khurram Nasir, Yale University, New Haven, CT, USA

### CURRENT CONCEPTS AND FUTURE DIRECTIONS IN ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROME

What is Considered to be the Optimal Treatment for Stable Angina in the Year 2012?

**Udho Thadani**, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK, USA

Can Vulnerable Plaque be Identified and Treated to Prevent Future Adverse CV Events?

John Ambrose, UCSF, Fresno, CA, USA

Robotic Assisted PCI: Results of the Precise Trial Using the Corpath, Remote Delivery System

George W. Vetrovec, VCU Pauley Heart Center, Richmond, VA, USA

Filling in the Gaps in the Treatment of Left Main Disease Barry Uretsky, University of Arkansas, Little Rock, AR, USA

Atherosclerosis as A Cause of Very Late Stent Thrombosis *Yasunori Ueda,* Osaka Police Hospital, Tennoj-ku, Osaka, Japan

Attributes of Statins in Reduction of Post-PCI Restenosis *Kailash Prasad*, Saskatchewan Saskatoon, SK, Canada

Antiplatelet Therapy in ACS: An Update in Personalized Medicine Jean-François Tanguay, Montreal Heart Institute, Montreal, Canada

Current Status of the use of IABP in Patients Undergoing Primary PCI for Cardiogenic Shock

Uwe Zeymer, Herzzentrum Ludwigshafen, Germany

**Embolic Protection in STEMI: When and How?** 

**Edo Kaluski**, Cardiac Catheterization Laboratories University Hospital, Newark, NJ, USA

### PATHOGENESIS, DIAGNOSES AND TREATMENT OF AORTIC ANEURYSMS AND PERIPHERAL ARTERY DISEASE

There is an Effective Medical Treatment for Thoracic Aortic Aneurysm *John A. Elefteriades*, Yale University School of Medicine, New Haven, CT, USA

The 2010 Aortic Guideline: What do they say and why? Angela T. Yetman, University of Utah, Salt Lake City, UT, USA

**Aortic Root and Ascending Aortic Pathologies: Indications for Operation and Surgical Options** 

Ali Khoynezhad, Cedars-Sinai Medical Center, Los Angeles, USA

Acute Aortic Diseases: Temporal Patterns of Onset and Clinical Outcome *Roberto Manfredini*, University of Ferrara, Italy

Coronary Artery, Cerebral Artery, and Abdominal Aortic Aneurysms:
Similarities in Pathogenesis and Implications for Treatment
S. David Gertz, The Hebrew University, Hadassah Faculty of Medicine, Jerusalem, Israel

### Prediction of Prognosis by Vacular Imagings in Pripheral Aretry Didease after Endovascular Treatment

Takanobu Tomaru, Toho University Sakura Hospital, Japan

A Novel Role of IgE in Abdominal aortic Aneurysms *Guo-Ping Shi*, Brigham and Women's Hospital, Boston, MA, USA

An Update on Endovascular Treatment of Peripheral Arterial Disease Subhash Banerjee, VA North Texas Healthcare System, Dallas, TX, USA

A New Concept of Stent: The Multilayer Flow Modulater: First Human Study in Arterial Aneurysms (AAA, TAAA...)

Michel Henry, Cabinet de Cardiologie, Nancy Cedex, France

#### **VALVULAR AND CONGENITAL HEART DISEASE**

The Impact of Hypertension and its Treatment in Heart Valve Disease Jeffrey S. Borer, State University of New York Downstate Medical Center, New York, NY, USA

PCI and TAVR Performance Measures: Onsite Versus Offsite Monitoring William J. Bommer, University of California Davis, Medical Center, CA, USA

Intervention in Adult Congenital Heart Disease especially Device Closure of ASD and Hypertensive Large PDA and Stenting in Coarctation of the Aorta *Masood Sadiq*, Punjab Institute of Cardiology, Lahore, Pakistan

Advances in Management of Valvular Heart Disease in the Elderly *Issam Mikati*, Radiology Feinberg School of Medicine, Chicago, IL, USA

Prosthetic Valve Thrombosis: Understanding the Guidelines Sorin Pislaru, Mayo Clinic College of Medicine, Rochester, MN, USA

Anticoagulation in Pregnant Women with Posthetic Valves **Sorel Goland**, Kaplan Hospital, Rehovot, Israel

### ADVANCES IN CARDIOVASCULAR SURGERY, CORONARY REVASCULARIZATION AND HEART TRANSPLANTATION

**Antibody Mediated Rejection in Heart Transplantation - A Clinician's Perspective** 

Maryl R. Johnson, University of Wisconsin-Madison, WI, USA

Role of CMV in Cardiac Allograft Vasculopathy

Nandini Nair, Texas A&M HSC College of Medicine, Temple, TX, USA

Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock in 2012: Have we Reached the Limit?

Vladimir Dzavik, University of Toronto, University Health Network, Toronto, ON, USA

The Complicated STEMI: What to do with Multivessel Disease *Gregory Barsness*, Mayo Clinic, Rochester, MN, USA

Management of Early Postoperative Coronary Bypass Graft Failure Louis P. Perrault, Montreal Heart Institute, Montreal, QC, Canada

Diabetes and Multivessel CAD: The Freedom Trial *Michael Farkouh*, Toronto General Hospital, ON, Canada

Hybrid Coronary Revascularization... Is it the Future of Coronary Revascularization (or) a Mere Flash in the Pan?

V.S. Srinivas, Jack D. Weiler Hospital of Montefiore Medical Center, Bronx, NY, USA

Off-Pump Coronary Artery Bypass Grafting: the Myth, the Reality *Shahzad G. Raja*, Harefield Hospital, London, UK

Coronary Artery Perforation-the Bane of an Interventional Cardiologist *Deepak Jain*, University Clinic Schleswig-Holstein, Lubeck, Germany